TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Baxter International ( (BAX) ).
On November 19, 2025, Baxter International announced an increase in the maximum purchase price for its cash tender offer for 1.915% Senior Unsecured Notes due 2027 from $300 million to $600 million. This move could impact Baxter’s financial strategy and market positioning by potentially increasing liquidity and financial flexibility.
The most recent analyst rating on (BAX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including high leverage and negative profitability, which are reflected in its valuation metrics. Technical indicators suggest a bearish trend, further weighing on the stock’s outlook. While the earnings call provides some positive guidance, the overall risks and challenges overshadow potential growth opportunities.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc. operates in the healthcare industry, providing essential solutions in hospitals, physician offices, and other care sites. The company offers a portfolio of connected solutions, medical devices, and advanced injectable technologies, serving millions of patients and healthcare providers globally.
Average Trading Volume: 7,136,868
Technical Sentiment Signal: Sell
Current Market Cap: $9.13B
For detailed information about BAX stock, go to TipRanks’ Stock Analysis page.